Related references
Note: Only part of the references are listed.Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects
R. Yu et al.
CELL DEATH & DISEASE (2013)
IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells
Chirlei Klein Bueneker et al.
CANCER LETTERS (2012)
Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL
Eva Szegezdi et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
Caroline M. M. van Geelen et al.
BMC CANCER (2011)
Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis
David Vindrieux et al.
CANCER CELL INTERNATIONAL (2011)
Targeting AML through DR4 with a novel variant of rhTRAIL
Eva Szegezdi et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
Unraveling the Binding Mechanism of Trivalent Tumor Necrosis Factor Ligands and Their Receptors
Carlos R. Reis et al.
MOLECULAR & CELLULAR PROTEOMICS (2011)
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
T. Trarbach et al.
BRITISH JOURNAL OF CANCER (2010)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors
Dominic Stadel et al.
CLINICAL CANCER RESEARCH (2010)
TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5
Johannes Lemke et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2010)
Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells
Andrea Mohr et al.
STEM CELLS (2010)
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
C. R. Reis et al.
CELL DEATH & DISEASE (2010)
Enhancement of Antitumor Properties of rhTRAIL by Affinity Increase toward Its Death Receptors
Carlos R. Reis et al.
BIOCHEMISTRY (2009)
Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma
Meike Vogler et al.
CANCER RESEARCH (2009)
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Michael R. Loebinger et al.
CANCER RESEARCH (2009)
Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model
Evelien W. Duiker et al.
CLINICAL CANCER RESEARCH (2009)
Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy
Lata G. Menon et al.
STEM CELLS (2009)
Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells against Intracranial Glioma
Seong Muk Kim et al.
CANCER RESEARCH (2008)
Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo
Meike Vogler et al.
CANCER RESEARCH (2008)
DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design
Vicente Tur et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model
Andrea Mohr et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release
A. Mohr et al.
ONCOGENE (2008)
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells
M. Vogler et al.
ONCOGENE (2007)
Constitutively activated nuclear factor-κB, but not induced NF-κB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells
Susanne J. Braeuer et al.
MOLECULAR CANCER RESEARCH (2006)
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2
Delphine Merino et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells
Sanaz Khanbolooki et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor
Almer M. van der Sloot et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Cancer gene therapy using a novel secretable trimeric TRAIL
CY Kim et al.
GENE THERAPY (2006)
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies
M MacFarlane et al.
CANCER RESEARCH (2005)
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
LD Zhang et al.
CANCER GENE THERAPY (2005)
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution
RF Kelley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression
A Mohr et al.
GENE THERAPY (2004)
The secretable form of trimeric TRAIL, a potent inducer of apoptosis
MH Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis
M Chawla-Sarkar et al.
CELL DEATH AND DIFFERENTIATION (2004)
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs
TM Ganten et al.
CELL DEATH AND DIFFERENTIATION (2004)
Following a TRAIL: Update on a ligand and its five receptors
FC Kimberley et al.
CELL RESEARCH (2004)
TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes:: Differential contribution of TRAIL receptors 1 and 2
M Leverkus et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc et al.
CELL DEATH AND DIFFERENTIATION (2003)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa et al.
NATURE MEDICINE (2001)
Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
H Wajant et al.
ONCOGENE (2001)
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
A Chuntharapai et al.
JOURNAL OF IMMUNOLOGY (2001)
Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis
S Hinz et al.
ONCOGENE (2000)
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
MR Sprick et al.
IMMUNITY (2000)
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
FC Kischkel et al.
IMMUNITY (2000)
TRAIL receptor-2 signals apoptosis through FADD and caspase-8
JL Bodmer et al.
NATURE CELL BIOLOGY (2000)
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL
SG Hymowitz et al.
BIOCHEMISTRY (2000)
Share Paper
